Weight Loss Outcomes Between GLP-1 Receptor Agonists and Bariatric Surgery in Adults
GLP-1 bariatric surgery meta-analysis evidence suggests bariatric surgery produced greater long-term weight and BMI reduction in the reviewed studies. The comparison also found stronger longer-term glycemic outcomes for surgery, while lipid and blood…
Weight Loss, Metabolic Health, and Psychiatric Safety
Semaglutide for schizophrenia weight gain is emerging as a focused metabolic strategy for patients whose antipsychotic treatment has created serious weight and glucose burden. This Evidence Watch review examines RCT meta-analysis data showing meaningful…
Use of Oral Semaglutide and Associated Clinical Outcomes in Thai Patients With Diabetes
The REALISED study shows significant improvements in HbA1c and body weight among Thai patients using oral semaglutide. No severe hypoglycaemia was reported.
Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic Patients
A study comparing Tirzepatide to Semaglutide in diabetic CABG patients found significant benefits for cerebrovascular and cardiovascular outcomes, reducing mortality and complications.
Systematic Characterisation of GLP-1R in Human Enteric Nervous System- Implicati
GLP-1R is abundantly expressed in the colonic enteric nervous system, preferentially in inhibitory neurons. This study provides insights into GLP-1 receptor agonist-induced gastrointestinal dysmotility.
Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia
A recent study indicates that tirzepatide may reduce incident dementia more than semaglutide or SGLT2 inhibitors in adults with type 2 diabetes.
The No-Hunger Games- How GLP-1 Medication Adoption Is Changing Consumer Food Dem
GLP-1 medications lead to significant reductions in grocery spending, particularly in calorie-dense foods. This impact persists during medication use but reverses upon discontinuation.
Beyond weight loss- tirzepatide as a dual GIP:GLP-1 receptor agonist for obstruc
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been FDA-approved for treating moderate-to-severe OSA in obese adults. It significantly reduces AHI and improves sleep quality.
Cancer Incidence Among Users of Glucagon‑Like Peptide‑1 Receptor Agonists
A study involving over 106,000 patients found that GLP-1RA use was associated with a significantly lower risk of liver and pancreatic cancer compared to insulin.
Cannabis policy priorities and public health- a survey of elected officials in California
This study reveals that among California elected officials, economic priorities dominate over health concerns. Despite cross-party consensus on youth packaging bans, implementation remains sparse.